Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment
| Status: | Terminated |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - 59 |
| Updated: | 9/27/2018 |
| Start Date: | June 2007 |
| End Date: | December 1, 2009 |
Evaluating the Efficacy of NeuroVisions's NVC Treatment for Low Myopia
The purpose of the present study is to carry out a trial to evaluate the clinical efficacy of
the NeuroVision Low Myopia Treatment.
The specific questions to be answered are:
1. Is there an improvement in vision following the treatment without bringing about a
change in the subject's prescription for glasses?
2. Can any treatment effect be seen at 6 months and 12 months after the termination of the
treatment?
the NeuroVision Low Myopia Treatment.
The specific questions to be answered are:
1. Is there an improvement in vision following the treatment without bringing about a
change in the subject's prescription for glasses?
2. Can any treatment effect be seen at 6 months and 12 months after the termination of the
treatment?
Myopia and its treatment modalities are one of the widely studied areas in vision research.
So far all the treatment options have been optical i.e., patients with myopia are either
corrected with spectacles, contact lenses or refractive surgery to provide clear vision.
NeuroVision's NVC vision correction technology will be a novel method in the treatment of low
myopia as the technology is directed at specific neuronal interactions at the level of the
visual cortex (area responsible for vision in the brain). It uses a non-invasive,
patient-specific treatment that purports to improve neuronal efficiency and induce
improvement in the overall ability to see due to a reduction in noise and increase in signal
strength. As visual perception quality depends both on the input received through the eye and
the processing in the visual cortex, NeuroVision's technology is hypothesized to compensate
for blurred (myopic) inputs, by enhancing neural processing.
We will conduct a clinical evaluation of the effectiveness of this system. The subject will
be exposed to a set of visual stimulations (pattern with black and white lines) and visual
threshold level will be obtained. The subject will look at these patterns on a computer. The
treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week,
for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity,
ability to see letters of varying size, and CSF, ability to see black and white lines of
varying contrast) will be tested in order to continuously monitor a subject's progress. At
the end of a session, the data will be sent to the NeuroVision Web Server. Proprietary
algorithmic software will analyze the patient's performance and progress and will generate
the parameters for the next treatment session. The purpose of the study is to assess the
effect on corrected or uncorrected visual performance following treatment.
So far all the treatment options have been optical i.e., patients with myopia are either
corrected with spectacles, contact lenses or refractive surgery to provide clear vision.
NeuroVision's NVC vision correction technology will be a novel method in the treatment of low
myopia as the technology is directed at specific neuronal interactions at the level of the
visual cortex (area responsible for vision in the brain). It uses a non-invasive,
patient-specific treatment that purports to improve neuronal efficiency and induce
improvement in the overall ability to see due to a reduction in noise and increase in signal
strength. As visual perception quality depends both on the input received through the eye and
the processing in the visual cortex, NeuroVision's technology is hypothesized to compensate
for blurred (myopic) inputs, by enhancing neural processing.
We will conduct a clinical evaluation of the effectiveness of this system. The subject will
be exposed to a set of visual stimulations (pattern with black and white lines) and visual
threshold level will be obtained. The subject will look at these patterns on a computer. The
treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week,
for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity,
ability to see letters of varying size, and CSF, ability to see black and white lines of
varying contrast) will be tested in order to continuously monitor a subject's progress. At
the end of a session, the data will be sent to the NeuroVision Web Server. Proprietary
algorithmic software will analyze the patient's performance and progress and will generate
the parameters for the next treatment session. The purpose of the study is to assess the
effect on corrected or uncorrected visual performance following treatment.
Inclusion Criteria:
- Age should be between 18 to 59 years
- Spherical equivalent in the worst eye should not exceed -1.5 DS and the astigmatism
should not exceed -0.75 DC.
- The subject's refractive status is stable, with no increase beyond 0.5D in sphere or
cylinder over the last six months. That is, the subject's spectacle prescription
should not differ from the auto-refraction value by 0.50D.
- Unaided visual acuity is 0.6 LogMAR or better in the eye with the poorer unaided
acuity
- Unaided visual acuity is 0.1 LogMAR or worse in the eye with better unaided acuity
- Unaided visual acuity difference between both eyes is less than 0.3 LogMAR
- Best-corrected visual acuity is 0.04 LogMAR or better in both eyes.
- The subject should be aware that the study has the following features:
1. The recommended pace for the treatment sessions is at least 3 sessions per week.
2. Interruptions should not be longer than 2 weeks during the treatment course.
Note: The subject is free to voluntarily withdraw from the study at any time.
Exclusion Criteria:
- The subject suffers from any other visually disabling eye disease(s) or other causes
for the reduced visual acuity, aside from myopia and/or astigmatism
- The subject suffers from myopia-related visual complications resulting in visual loss,
including myopic macular degeneration, myopic cataract and previous or pre-existing
myopic retinal detachment.
- The subject is suffering from Diabetes Mellitus.
- The subject suffers from Migraines
- The subject suffers from Epilepsy
- The subject is pregnant. (It is not recommended to include pregnant women because of
the expected visual fluctuations. The NV treatment , basically using a computer, has
no impact on the pregnancy.) No pregnancy testing will be done but will be identified
through verbal history. The study has use of tropicamide drug (dilation drops) and
proparacaine (topical anesthetic), which are a routinely used eye drop in everyday
clinical practice and no adverse effects have been reported so far on pregnant women
or fetus.
- The subject has an activity limitation due to medical disorders (including migraines,
seizure disorders, etc.), medications, or emotional status that might potentially
impair the subject's ability to perform the treatment.
We found this trial at
1
site
Click here to add this to my saved trials
